State Street Corp Purchases 3,839 Shares of Omeros Co. (NASDAQ:OMER)

State Street Corp boosted its stake in shares of Omeros Co. (NASDAQ:OMER) by 0.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,226,053 shares of the biopharmaceutical company’s stock after buying an additional 3,839 shares during the quarter. State Street Corp’s holdings in Omeros were worth $4,867,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. HighTower Advisors LLC grew its holdings in Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 4,000 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the period. Bank of New York Mellon Corp raised its position in Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Omeros in the 2nd quarter valued at $105,000. Finally, SPC Financial Inc. purchased a new position in Omeros in the third quarter valued at $77,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Rodman & Renshaw assumed coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Thursday, December 19th. Finally, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Price Performance

Shares of NASDAQ:OMER opened at $11.68 on Monday. Omeros Co. has a 12 month low of $2.61 and a 12 month high of $13.60. The business has a 50-day moving average of $7.73 and a two-hundred day moving average of $5.43. The firm has a market capitalization of $676.86 million, a PE ratio of -5.06 and a beta of 1.97.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.